X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Impressive results from E Merck - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Impressive results from E Merck

Apr 25, 2000

A 10% increase in sales has lead to tripling of profits at the net level. This has to do with the fact that last year the company provided Rs 27 m for the VRS payments to workers and closed its Taloja plant. However, even if one were to add this back to the last year's pre-tax profit, the net profit has still grown by 55%.

Besides, E Merck repaid almost a third of its borrowings last year which has led to a 32% decline in the interest payments and contributed to the surge in the bottomline.

(Rs m) FY99 FY00 Change
Sales 615 676 9.8%
Other Income 10 13 23.8%
Expenditure 575 589 2.5%
Operating Profit (EBDIT) 41 87 113.8%
Operating Profit Margin (%) 7% 13%  
Interest 10 7 -32.1%
Depreciation 17 21 20.8%
Profit before Tax 24 72 201.7%
Other Adjustments      
Tax 7 22 234.3%
Profit after Tax/(Loss) 18 51 189.7%
Net profit margin (%) 2.8% 7.5%  

E Merck derives almost 70% of the vitamins with three products Evion, Polybion and Neurobion contributing almost 45% of the company's turnover. All the three are under price control and are likely to remain that way for some time to come.

The company has introduced products in the cardiovascular and dermatological segments both of which are out of price control and these should boost revenues in the future.

The company's stock price performance is in sharp contrast to its fundamentals. In line with other pharmaceutical stocks the company's stock has also been hammered and actually touched its 52 week low (Rs 260) yesterday! This could be partially explained by the apprehension created due to a wrong news report which said that government has banned vitamins B1, B6 and B12 from January 2001. Since E Merck is the bigget player in this segment, this meant that the future revenues would be hit. However, the actual fiat was with respect of injectibles of an irrational combination of B1, B6 and B12 which has already been banned worldwide. Thus the company can continue selling these vitamins in the oral or injectable form except for the particular combination. However the fall in stock price represents a good opportunity for long term investors.


Equitymaster requests your view! Post a comment on "Impressive results from E Merck". Click here!

  

More Views on News

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

MERCK SHARE PRICE


May 24, 2019 (Close)

TRACK MERCK

MERCK - TEVA PHARMA COMPARISON

COMPARE MERCK WITH

MARKET STATS